Download PDF
Facial Plast Surg 2024; 40(02): 252-266
DOI: 10.1055/a-2196-4713
Original Article

Medical Treatment for Androgenetic Alopecia

Ratchathorn Panchaprateep 
1   Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2   Absolute Hair Clinic, Bangkok Thailand
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Androgenetic alopecia is a common type of hair loss, which is generally influenced by genetic factors and systemic androgens resulting in follicular miniaturization.[1] It can cause cosmetic problems leading to psychological distress among affected men and women. Effective standard medical treatments available are topical minoxidil 2 to 5%, oral finasteride, oral dutasteride, and hair transplantation.[1] However, some patients do not achieve favorable results with standard treatments. For these reasons, other novel treatments have been developed, including new medications, regenerative medicines (autologous platelet-rich plasma, adipose-derived stem cells, micrograft generation, and exosome), and low-level laser therapy

Keywords

medical treatment - finasteride - minoxidil lotion - dutasteride - oral minoxidil - platelet-rich plasma


Publication History

Accepted Manuscript online:
23 October 2023

Article published online:
04 December 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Olsen EADF, Dunlap FE, Funicella T. et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47 (03) 377-385
    CrossrefPubMedGoogle Scholar
  • 2 Bienová M, Kucerová R, Fiurásková M, Hajdúch M, Koláŕ Z. Androgenetic alopecia and current methods of treatment. Acta Dermatovenerol Alp Panonica Adriat 2005; 14 (01) 5-8
    PubMedGoogle Scholar
  • 3 Katzer T, Leite Junior A, Beck R, da Silva C. Physiopathology and current treatments of androgenetic alopecia: going beyond androgens and anti-androgens. Dermatol Ther 2019; 32 (05) e13059
    CrossrefPubMedGoogle Scholar
  • 4 Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic alopecia: therapy update. Drugs 2023; 83 (08) 701-715
    CrossrefPubMedGoogle Scholar
  • 5 Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol 2021; 20 (12) 3759-3781
    CrossrefPubMedGoogle Scholar
  • 6 Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004; 150 (02) 186-194
    CrossrefPubMedGoogle Scholar
  • 7 Piraccini BM, Blume-Peytavi U, Scarci F. et al; Topical Finasteride Study Group. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol 2022; 36 (02) 286-294
    CrossrefPubMedGoogle Scholar
  • 8 Bajoria PS, Dave PA, Rohit RK. et al. Comparing current therapeutic modalities of androgenic alopecia: a literature review of clinical trials. Cureus 2023; 15 (07) e42768
    PubMedGoogle Scholar
  • 9 Deoghare S, Sadick NS. Combination therapy in female pattern hair loss. J Cosmet Laser Ther 2023; 25 (1-4): 1-6
    CrossrefPubMedGoogle Scholar
  • 10 Saceda-Corralo D, Domínguez-Santas M, Vañó-Galván S, Grimalt R. What's new in therapy for male androgenetic alopecia?. Am J Clin Dermatol 2023; 24 (01) 15-24
    CrossrefPubMedGoogle Scholar
  • 11 Suchonwanit P, Iamsumang W, Leerunyakul K. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. J Dermatolog Treat 2022; 33 (02) 643-648
    CrossrefPubMedGoogle Scholar
  • 12 Saceda-Corralo D, Domínguez-Santas M, Vano-Galvan S. et al. What's new in therapy for male androgenetic alopecia?. Am J Clin Dermatol 2023; 24: 15-24
    CrossrefPubMedGoogle Scholar
  • 13 Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. J Eur Acad Dermatol Venereol 2018; 32 (12) 2257-2263
    CrossrefPubMedGoogle Scholar
  • 14 Dallob AL, Sadick NS, Unger W. et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994; 79 (03) 703-706
    PubMedGoogle Scholar
  • 15 Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol 2002; 46 (04) 517-523
    CrossrefPubMedGoogle Scholar
  • 16 Stough DB, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol 2002; 12 (01) 32-37
    PubMedGoogle Scholar
  • 17 Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol 2016; 82 (02) 128-134
    CrossrefPubMedGoogle Scholar
  • 18 Melo DF, de Mattos Barreto T, Plata GT, Araujo LR, Tortelly VD. Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia. J Cosmet Dermatol 2020; 19 (01) 75-77
    CrossrefPubMedGoogle Scholar
  • 19 Sato A, Takeda A. Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol 2012; 39 (01) 27-32
    CrossrefPubMedGoogle Scholar
  • 20 Overstreet JW, Fuh VL, Gould J. et al. Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J Urol 1999; 162 (04) 1295-1300
    CrossrefPubMedGoogle Scholar
  • 21 Liu KEBS, Lo KC, Jarvi K. Propecia-induced spermatogenesis failure: a report of two cases. Fertil Steril 2008; 90: 849
    PubMedGoogle Scholar
  • 22 Kim WJ, Song M, Ko HC, Kim BS, Kim MB. Efficacy of finasteride 1.25 mg on female pattern hair loss; pilot study. Ann Dermatol 2012; 24 (03) 370-37
    CrossrefPubMedGoogle Scholar
  • 23 Won YY, Lew BL, Sim WY. Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss. Dermatol Ther 2018; 31 (02) e12588
    PubMedGoogle Scholar
  • 24 Iamsumang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Devel Ther 2020; 14: 951-959
    CrossrefPubMedGoogle Scholar
  • 25 Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-α reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatol 2022; 158 (03) 266-274
    CrossrefPubMedGoogle Scholar
  • 26 Gupta AK, Talukder M, Williams G. Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatolog Treat 2022; 33 (07) 2946-2962
    CrossrefPubMedGoogle Scholar
  • 27 Olsen EA, Hordinsky M, Whiting D. et al; Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55 (06) 1014-1023
    CrossrefPubMedGoogle Scholar
  • 28 Amory JKWC, Swerdloff RS. et al. The effect of 5-alpha-reductase on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007; 92: 1659-1665
    CrossrefPubMedGoogle Scholar
  • 29 Georgala S, Katoulis AC, Befon A, Danopoulou I, Georgala C. Treatment of postmenopausal frontal fibrosing alopecia with oral dutasteride. J Am Acad Dermatol 2009; 61 (01) 157-158
    CrossrefPubMedGoogle Scholar
  • 30 Katoulis A, Georgala, Bozi E, Papadavid E, Kalogeromitros D, Stavrianeas N. Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus. J Eur Acad Dermatol Venereol 2009; 23 (05) 580-582
    CrossrefPubMedGoogle Scholar
  • 31 Pindado-Ortega C, Saceda-Corralo D, Moreno-Arrones OM. et al. Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice. J Am Acad Dermatol 2021; 84 (05) 1285-1294
    CrossrefPubMedGoogle Scholar
  • 32 Rozner RN, Freites-Martinez A, Shapiro J, Geer EB, Goldfarb S, Lacouture ME. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast Cancer Res Treat 2019; 174 (01) 15-26
    CrossrefPubMedGoogle Scholar
  • 33 Rodríguez-Cuadrado FJ, Pinto-Pulido EL, Fernández-Parrado M. Mesotherapy with dutasteride for androgenetic alopecia: a concise review of the literature. Eur J Dermatol 2023; 33 (01) 72
    CrossrefPubMedGoogle Scholar
  • 34 Saceda-Corralo D, Moustafa F, Moreno-Arrones Ó, Jaén-Olasolo P, Vañó-Galván S, Camacho F. Mesotherapy with dutasteride for androgenetic alopecia: a retrospective study in real clinical practice. J Drugs Dermatol 2022; 21 (07) 742-747
    PubMedGoogle Scholar
  • 35 Saceda-Corralo D, Rodrigues-Barata AR, Vañó-Galván S, Jaén-Olasolo P. Mesotherapy with dutasteride in the treatment of androgenetic alopecia. Int J Trichology 2017; 9 (03) 143-145
    CrossrefPubMedGoogle Scholar
  • 36 Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol 2018; 57 (01) 104-109
    CrossrefPubMedGoogle Scholar
  • 37 Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment. Dermatol Ther (Heidelb) 2020; 10 (06) 1345-1357
    CrossrefPubMedGoogle Scholar
  • 38 Jha AK, Sonthalia S, Zeeshan MD, Vinay K. Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia. J Am Acad Dermatol 2020; 83 (05) 1491-1493
    CrossrefPubMedGoogle Scholar
  • 39 Olamiju B, Craiglow BG. Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls. J Am Acad Dermatol 2021; 84 (06) 1689-1691
    CrossrefPubMedGoogle Scholar
  • 40 Pirmez R, Salas-Callo CI. Very-low-dose oral minoxidil in male androgenetic alopecia: a study with quantitative trichoscopic documentation. J Am Acad Dermatol 2020; 82 (01) e21-e22
    CrossrefPubMedGoogle Scholar
  • 41 Vastarella M, Cantelli M, Patrì A, Annunziata MC, Nappa P, Fabbrocini G. Efficacy and safety of oral minoxidil in female androgenetic alopecia. Dermatol Ther 2020; 33 (06) e14234
    CrossrefPubMedGoogle Scholar
  • 42 Yin L, Svigos K, Gutierrez D, Peterson E, Lo Sicco K, Shapiro J. Low-dose oral minoxidil increases hair density and thickness in androgenetic alopecia: a retrospective analysis of 60 patients. J Eur Acad Dermatol Venereol 2022; 36 (03) e200-e202
    PubMedGoogle Scholar
  • 43 Gomolin A, Litvinov IV, Netchiporouk E. Oral minoxidil: a possible new therapy for androgenetic alopecia. J Cutan Med Surg 2020; 24 (01) 88-89
    CrossrefPubMedGoogle Scholar
  • 44 Ramos Sr PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial. J Am Acad Dermatol 2020; 82 (01) 252-253
    CrossrefPubMedGoogle Scholar
  • 45 Gupta AK, Hall DC, Talukder M, Bamimore MA. There is a positive dose-dependent association between low-dose oral minoxidil and its efficacy for androgenetic alopecia: findings from a systematic review with meta-regression analyses. Skin Appendage Disord 2022; 8 (05) 355-361
    CrossrefPubMedGoogle Scholar
  • 46 Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R. et al. Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data. Dermatol Ther 2020; 33 (06) e14106
    CrossrefPubMedGoogle Scholar
  • 47 Rodrigues-Barata R, Moreno-Arrones OM, Saceda-Corralo D. et al. Low-dose oral minoxidil for female pattern hair loss: a unicenter descriptive study of 148 women. Skin Appendage Disord 2020; 6 (03) 175-176
    CrossrefPubMedGoogle Scholar
  • 48 Vastarella M, Cantelli M, Fabbrocini G, Ocampo-Garza SS. Could oral minoxidil be superior to its topical variant for treatment of female pattern hair loss?. Ital J Dermatol Venereol 2023; 158 (03) 270-272
    CrossrefPubMedGoogle Scholar
  • 49 Bokhari L, Jones LN, Sinclair RD. Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial. J Eur Acad Dermatol Venereol 2022; 36 (01) e62-e66
    CrossrefPubMedGoogle Scholar
  • 50 Aleissa M. The efficacy and safety of oral spironolactone in the treatment of female pattern hair loss: a systematic review and meta-analysis. Cureus 2023; 15 (08) e43559
    PubMedGoogle Scholar
  • 51 Burns LJ, De Souza B, Flynn E, Hagigeorges D, Senna MM. Spironolactone for treatment of female pattern hair loss. J Am Acad Dermatol 2020; 83 (01) 276-278
    CrossrefPubMedGoogle Scholar
  • 52 Bazargan AS, Tavana Z, Dehghani A. et al. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: a blinded randomized clinical trial. J Cosmet Dermatol 2023; (e-pub ahead of print) DOI: 10.1111/jocd.15979.
    CrossrefPubMedGoogle Scholar
  • 53 Carmina E, Azziz R, Bergfeld W. et al. Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee. J Clin Endocrinol Metab 2019; 104 (07) 2875-2891
    CrossrefPubMedGoogle Scholar
  • 54 Carvalho RM, Santos LDN, Ramos PM. et al. Bicalutamide and the new perspectives for female pattern hair loss treatment: what dermatologists should know. J Cosmet Dermatol 2022; 21 (10) 4171-4175
    CrossrefPubMedGoogle Scholar
  • 55 Fernandez-Nieto D, Saceda-Corralo D, Jimenez-Cauhe J. et al. Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss. J Am Acad Dermatol 2020; 83 (05) e355-e356
    CrossrefPubMedGoogle Scholar
  • 56 Fernandez-Nieto D, Saceda-Corralo D, Rodrigues-Barata R. et al. Oral bicalutamide for female pattern hair loss: a pilot study. Dermatol Ther 2019; 32 (06) e13096
    CrossrefPubMedGoogle Scholar
  • 57 Ismail FF, Meah N, Trindade de Carvalho L, Bhoyrul B, Wall D, Sinclair R. Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients. J Am Acad Dermatol 2020; 83 (05) 1478-1479
    CrossrefPubMedGoogle Scholar
  • 58 Moussa A, Kazmi A, Bokhari L, Sinclair RD. Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: a retrospective review of 35 patients. J Am Acad Dermatol 2022; 87 (02) 488-490
    CrossrefPubMedGoogle Scholar
  • 59 Alves R, Grimalt R. Randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. Dermatol Surg 2016; 42 (04) 491-497
    CrossrefPubMedGoogle Scholar
  • 60 Gupta AK, Versteeg SG, Rapaport J, Hausauer AK, Shear NH, Piguet V. The efficacy of platelet-rich plasma in the field of hair restoration and facial aesthetics—a systematic review and meta-analysis. J Cutan Med Surg 2019; 23 (02) 185-203
    CrossrefPubMedGoogle Scholar
  • 61 Georgescu SR, Amuzescu A, Mitran CI. et al. Effectiveness of platelet-rich plasma therapy in androgenic alopecia—a meta-analysis. J Pers Med 2022; 12 (03) 342
    CrossrefPubMedGoogle Scholar
  • 62 Lotfi E, Aramianpour N, Salehi B. Combination of platelet-rich plasma and platelet gel in treatment of resistance androgenic alopecia: a case series study. J Cosmet Dermatol 2022; 21 (10) 4307-4312
    CrossrefPubMedGoogle Scholar
  • 63 Gupta AK, Bamimore M. Platelet-rich plasma monotherapies for androgenetic alopecia: a network meta-analysis and meta-regression study. J Drugs Dermatol 2022; 21 (09) 943-952
    CrossrefPubMedGoogle Scholar
  • 64 de Oliveira AFQ, Arcanjo FPN, Rodrigues MRP, Rosa E Silva AA, Hall PR. Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis. J Dermatolog Treat 2023; 34 (01) 2138692
    CrossrefPubMedGoogle Scholar
  • 65 Papakonstantinou M, Siotos C, Gasteratos KC, Spyropoulou GA, Gentile P. Autologous platelet-rich plasma treatment for androgenic alopecia: a systematic review and meta-analysis of clinical trials. Plast Reconstr Surg 2023; 151 (05) 739e-747e
    CrossrefPubMedGoogle Scholar
  • 66 Hetz SP, Martin J, Pototschnig H. Patient satisfaction and clinical effects of platelet-rich plasma on pattern hair loss in male and female patients. Cureus 2022; 14 (09) e28801
    PubMedGoogle Scholar
  • 67 Thuangtong R, Chaweekulrat P, Thanomkitti K, Triwongwaranat D, Rujitharanawong C. Effect of platelet-rich plasma and other key factors on hair follicle preservation. Int J Trichology 2023; 15 (02) 50-55
    CrossrefPubMedGoogle Scholar
  • 68 Wang S, Li D, Zou M. et al. Efficacy of autologous platelet-rich plasma combined with a non-cross-linked hyaluronic acid compound in the treatment of female androgenetic alopecia: a retrospective, case-series study. J Cosmet Dermatol 2023; (e-pub ahed of print) DOI: 10.1111/jocd.15861.
    CrossrefPubMedGoogle Scholar
  • 69 Zhang X, Ji Y, Zhou M. et al. Platelet-rich plasma for androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. J Cutan Med Surg 2023; (e-pub ahead of print) DOI: 10.1177/12034754231191461.
    CrossrefPubMedGoogle Scholar
  • 70 Li C, Pan L, Yang L, Kong J, Zhang L. An umbrella review of the use of platelet-rich plasma in the treatment of androgenetic alopecia. J Cosmet Dermatol 2023; 22 (05) 1463-1476
    CrossrefPubMedGoogle Scholar
  • 71 Asim M, Shah R, Sharif S, Ouellette S, Shah A, Rao B. A randomized control trial comparing the efficacy of platelet-rich plasma and 5% topical minoxidil for the treatment of androgenetic alopecia. J Drugs Dermatol 2023; 22 (09) 905-909
    PubMedGoogle Scholar
  • 72 Balasundaram M, Kumari R, Ramassamy S. Efficacy of autologous platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: a randomized open-label trial. J Dermatolog Treat 2023; 34 (01) 2182618
    CrossrefPubMedGoogle Scholar
  • 73 Cedirian S, Bruni F, Quadrelli F. et al. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia. J Cosmet Dermatol 2023; (e-pub ahead of print) DOI: 10.1111/jocd.15873.
    CrossrefPubMedGoogle Scholar
  • 74 Kaiser M, Abdin R, Gaumond SI, Issa NT, Jimenez JJ. Treatment of androgenetic alopecia: current guidance and unmet needs. Clin Cosmet Investig Dermatol 2023; 16: 1387-1406
    CrossrefPubMedGoogle Scholar
  • 75 Abdelkader R, Abdalbary S, Naguib I, Makarem K. Effect of platelet rich plasma versus saline solution as a preservation solution for hair transplantation. Plast Reconstr Surg Glob Open 2020; 8 (06) e2875
    CrossrefPubMedGoogle Scholar
  • 76 Pathania V, Sood A, Beniwal N, Baveja S, Shankar P, Patrikar S. Randomized control trial to study the efficacy and safety of platelet-rich plasma as intraoperative holding solution in hair restoration surgery: a pilot study. Med J Armed Forces India 2023; 79 (01) 46-53
    CrossrefPubMedGoogle Scholar
  • 77 Lueangarun S, Visutjindaporn P, Parcharoen Y, Jamparuang P, Tempark T. A systematic review and meta-analysis of randomized controlled trials of United States Food and Drug Administration-approved, home-use, low-level light/laser therapy devices for pattern hair loss: device design and technology. J Clin Aesthet Dermatol 2021; 14 (11) E64-E75
    PubMedGoogle Scholar
  • 78 Gupta AK, Carviel JL. Meta-analysis of photobiomodulation for the treatment of androgenetic alopecia. J Dermatolog Treat 2021; 32 (06) 643-647
    CrossrefPubMedGoogle Scholar
  • 79 Liu KH, Liu D, Chen YT, Chin SY. Comparative effectiveness of low-level laser therapy for adult androgenic alopecia: a system review and meta-analysis of randomized controlled trials. Lasers Med Sci 2019; 34 (06) 1063-1069
    CrossrefPubMedGoogle Scholar
  • 80 Kim TH, Kim NJ, Youn JI. Evaluation of wavelength-dependent hair growth effects on low-level laser therapy: an experimental animal study. Lasers Med Sci 2015; 30 (06) 1703-1709
    CrossrefPubMedGoogle Scholar
  • 81 Najem I, Chen H. Use of low-level laser therapy in treatment of the androgenic alopecia, the first systematic review. J Cosmet Laser Ther 2018; 20 (04) 252-257
    CrossrefPubMedGoogle Scholar
  • 82 Delaney SW, Zhang P. Systematic review of low-level laser therapy for adult androgenic alopecia. J Cosmet Laser Ther 2018; 20 (04) 229-236
    CrossrefPubMedGoogle Scholar
  • 83 Gupta AK, Bamimore MA, Foley KA. Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. J Dermatolog Treat 2022; 33 (01) 62-72
    CrossrefPubMedGoogle Scholar
  • 84 Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol 2017; 77 (01) 136-141.e5
    CrossrefPubMedGoogle Scholar
  • 85 Gupta AK, Mays RR, Dotzert MS, Versteeg SG, Shear NH, Piguet V. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. J Eur Acad Dermatol Venereol 2018; 32 (12) 2112-2125
    CrossrefPubMedGoogle Scholar
  • 86 Gentile P, Scioli MG, Bielli A, Orlandi A, Cervelli V. Stem cells from human hair follicles: first mechanical isolation for immediate autologous clinical use in androgenetic alopecia and hair loss. Stem Cell Investig 2017; 4: 58
    CrossrefPubMedGoogle Scholar
  • 87 Ghorbani R, Hosseinzadeh S, Azari A. et al. The current status and future direction of extracellular nano-vesicles in the alleviation of skin disorders. Curr Stem Cell Res Ther 2023 (e-pub ahead of print).Doi: 10.2174/1574888. Doi: X18666230418121053
    PubMedGoogle Scholar
  • 88 Egger A, Tomic-Canic M, Tosti A. Advances in stem cell-based therapy for hair loss. CellR4 Repair Replace Regen Reprogram 2020; 8: e2894
    PubMedGoogle Scholar
  • 89 Ariyoshi K, Hiroyama Y, Fujiwara N. et al. Extracellular vesicles released from irradiated neonatal mouse cheek tissue increased cell survival after radiation. J Radiat Res (Tokyo) 2021; 62 (01) 73-78
    CrossrefPubMedGoogle Scholar
  • 90 Liang Y, Tang X, Zhang X, Cao C, Yu M, Wan M. Adipose mesenchymal stromal cell-derived exosomes carrying MiR-122-5p antagonize the inhibitory effect of dihydrotestosterone on hair follicles by targeting the TGF-β1/SMAD3 signaling pathway. Int J Mol Sci 2023; 24 (06) 5703
    CrossrefPubMedGoogle Scholar
  • 91 Li Y, Wang G, Wang Q, Zhang Y, Cui L, Huang X. Exosomes secreted from adipose-derived stem cells are a potential treatment agent for immune-mediated alopecia. J Immunol Res 2022; 2022: 7471246
    PubMedGoogle Scholar
  • 92 Gupta AK, Renaud HJ, Halaas Y, Rapaport JA. Exosomes: a new effective non-surgical therapy for androgenetic alopecia?. Skinmed 2020; 18 (02) 96-100
    PubMedGoogle Scholar
  • 93 Kost Y, Muskat A, Mhaimeed N, Nazarian RS, Kobets K. Exosome therapy in hair regeneration: a literature review of the evidence, challenges, and future opportunities. J Cosmet Dermatol 2022; 21 (08) 3226-3231
    CrossrefPubMedGoogle Scholar
  • 94 Kim H, Jang Y, Kim EH. et al. Potential of colostrum-derived exosomes for promoting hair regeneration through the transition from telogen to anagen phase. Front Cell Dev Biol 2022; 10: 815205
    CrossrefPubMedGoogle Scholar
  • 95 Gupta AK, Wang T, Rapaport JA. Systematic review of exosome treatment in hair restoration: preliminary evidence, safety, and future directions. J Cosmet Dermatol 2023; 22 (09) 2424-2433
    CrossrefPubMedGoogle Scholar
  • 96 Wang G, Wang Z, Zhang J. et al. Treatment of androgenetic alopecia by exosomes secreted from hair papilla cells and the intervention effect of LTF. J Cosmet Dermatol 2023; 22 (11) 2996-3007
    CrossrefPubMedGoogle Scholar
  • 97 Hebert A, Thiboutot D, Stein Gold L. et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol 2020; 156 (06) 621-630
    CrossrefPubMedGoogle Scholar
  • 98 Rosette C, Rosette N, Mazzetti A, Moro L, Gerloni M. Cortexolone 17α-propionate (clascoterone) is an androgen receptor antagonist in dermal papilla cells in vitro. J Drugs Dermatol 2019; 18 (02) 197-201
    PubMedGoogle Scholar
  • 99 Dhillon S. Clascoterone: first approval. Drugs 2020; 80 (16) 1745-1750
    CrossrefPubMedGoogle Scholar
  • 100 Sun HY, Sebaratnam DF. Clascoterone as a novel treatment for androgenetic alopecia. Clin Exp Dermatol 2020; 45 (07) 913-914
    CrossrefPubMedGoogle Scholar
  • 101 Täubel J, Mazzetti A, Ferber G. et al. A phase 1 study to investigate the effects of cortexolone 17α-propionate, also known as clascoterone, on the QT interval using the meal effect to demonstrate ECG assay sensitivity. Clin Pharmacol Drug Dev 2021; 10 (06) 572-581
    CrossrefPubMedGoogle Scholar
  • 102 Fields JR, Vonu PM, Monir RL, Schoch JJ. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Dermatol Ther 2020; 33 (01) e13202
    CrossrefPubMedGoogle Scholar
  • 103 Chen X, Xiang H, Yang M. Topical cetirizine for treating androgenetic alopecia: A systematic review. J Cosmet Derma tol 2022; 21 (11) 5519-5526
    CrossrefPubMedGoogle Scholar
  • 104 Kanti V, Messenger A, Dobos G. et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men -short version. J Eur Acad Dermatol Venereol 2018; 32 (01) 11-22
    CrossrefPubMedGoogle Scholar
  • 105 Manabe M, Tsuboi R, Itami S. et al. Drafting Committee for the Guidelines for the Diagnosis and Treatment of Male-and Female-Pattern Hair Loss. Guidelines for the diagnosis and treatment ofmale-pattern and female-pattern hair loss, 2017 version. J Dermatol 2018; 45: 1031-1043
    CrossrefPubMedGoogle Scholar
  • 106 Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des, Develop Ther 2019; 13: 2777-2786
    CrossrefPubMedGoogle Scholar
  • 107 Vañó-Galván S, Pirmez R, Hermosa-Gelbard A. et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Amer Acad Dermatol 2021; 84 (06) 1644-1651
    CrossrefPubMedGoogle Scholar